Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice

American Journal of Respiratory and Critical Care Medicine

Volumn 179, Issue 11, 2009, Pages 1022-1028

  Lubamba, Bob ^a   Lebacq, Jean ^a   Lebecque, Patrick ^a   Vanbever, Rita ^a   Leonard, Anissa ^a   Wallemacq, Pierre ^a   Leal, Teresinha ^a,b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Chloride transport; Cystic fibrosis; Miglustat; Nasal potential difference; Sodium transport

Indexed keywords

4,4' DIISOTHIOCYANATOSTILBENE 2,2' DISULFONIC ACID; AMILORIDE; CHLORIDE CHANNEL; FORSKOLIN; MIGLUSTAT; PLACEBO; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHLORIDE TRANSPORT; CONTROLLED STUDY; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; GAUCHER DISEASE; HYPERPOLARIZATION; IN VIVO STUDY; KNOCKOUT MOUSE; LOW DRUG DOSE; MOUSE; NONHUMAN; NOSE MUCOSA; PRIORITY JOURNAL; PROTEIN TRANSPORT; SINGLE DRUG DOSE; SODIUM CONDUCTANCE; SODIUM TRANSPORT;

1-DEOXYNOJIRIMYCIN; ADMINISTRATION, INTRANASAL; ANIMALS; CHLORIDE CHANNELS; CYSTIC FIBROSIS; ENZYME INHIBITORS; MICE; MICE, KNOCKOUT; SODIUM CHANNELS;

EID: 66249120003     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200901-0049OC     Document Type: Article

References (42)

1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352:1992-2001. (Pubitemid 40638370)
2. Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med 2006;173:475-482.
3. Stutts MJ, Rossier BC, Boucher RC. Cystic fibrosis transmembrane conductance regulator inverts protein kinase A-mediated regulation of epithelial sodium channel single channel kinetics. J Biol Chem 1997;272:14037-14040. (Pubitemid 27232803)
4. Ismailov II, Awayda MS, Jovov B, Berdiev BK, Fuller CM, Dedman JR, Kaetzel M, Benos DJ. Regulation of epithelial sodium channels by the cystic fibrosis transmembrane conductance regulator. J Biol Chem 1996;271:4725-4732. (Pubitemid 26074954)
5. Cheng SH, Rich DP, Marshall J, Gregory RJ, Welsh MJ, Smith AE. Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel. Cell 1991;66:1027-1036. (Pubitemid 121001734)
6. Gregory RJ, Rich DP, Cheng SH, Souza DW, Paul S, Manavalan P, Anderson MP, Welsh MJ, Smith AE. Maturation and function of cystic fibrosis transmembrane conductance regulator variants bearing mutations in putative nucleotide-binding domains 1 and 2. Mol Cell Biol 1991;11:3886-3893. (Pubitemid 21895777)
7. Lukacs GL, Mohamed A, Kartner N, Chang XB, Riordan JR, Grinstein S. Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. EMBO J 1994;13:6076-6086.
8. Rowe SM, Accurso F, Clancy JP. Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc Am Thorac Soc 2007;4:387-398. (Pubitemid 47330876)
9. Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Aviram M, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008;372:719-727.
10. Lubamba B, Lecourt H, Lebacq J, Lebecque P, De Jonge H, Wallemacq P, Leal T. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med 2008;177:506-515.
11. Carvalho-Oliveira I, Scholte BJ, Penque D. What have we learned from mouse models for cystic fibrosis? Expert Rev Mol Diagn 2007;7:407-417.
12. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Herebicek M, Platt F, Butters T, Dwek R, Moyses C, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000;355:1481-1485. (Pubitemid 30237353)
13. Cox TM, Aerts JM, Andria G, Beck M, Belmatoug N, Bembi B, Chertkoff R, Vom Dahl S, Elstein D, Erikson A, et al.; Advisory Council to the European Working Group on Gaucher Disease. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 2003;26:513-526.
14. Elstein D, Hollak C, Aerts JMF, van Weely S, Maas M, Cox TM, Lachmann RH, Hrebicek M, Platt FM, Butters TD, et al. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT918) in type I Gaucher disease. J Inherit Metab Dis 2004;27:757-766. (Pubitemid 39433603)
15. Butters TD, Dwek RA, Platt FM. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. Glycobiology 2005;15:43R-52R. (Pubitemid 41511483)
16. Jacob JR, Mansfiels K, You JR, Tennant BC, Kim YH. Natural iminosugar derivatives of 1-deoxynojirimycin inhibit glycosylation of hepatitis viral envelope proteins. J Microbiol 2007;45:431-440. (Pubitemid 350023378)
17. Chapel C, Garcia C, Roingeard P, Zitzmann N, Dubuisson J, Dwek RA, Trépo C, Zoulim F, Durantel D. Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles. J Gen Virol 2006;87:861-871.
18. Norez C, Noel S, Wilke M, Bijvelds M, Jorna H, Melin P, DeJonge H, Becq F. Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Lett 2006;580:2081-2086.
19. Antigny F, Norez C, Becq F, Vandebrouck C. Calcium homeostasis is abnormal in cystic fibrosis airway epithelial cells but is normalized after rescue of F508del-CFTR. Cell Calcium 2008;43:175-183.
20. Noël S, Wilke M, Bot AG, De Jonge HR, Becq F. Parallel improvement of sodium and chloride transport defects by miglustat (n-butyldeoxynojyrimicin) in cystic fibrosis epithelial cells. J Pharmacol Exp Ther 2008;325:1016-1023.
21. Dechecchi MC, Nicolis E, Norez C, Bezzerri V, Borgatti M, Mancini I, Rizzotti P, Ribeiro CM, Gambari R, Becq F, et al. Anti-inflammatory effect of miglustat in bronchial epithelial cells. J Cyst Fibros 2008;7:555-565.
22. Norez C, Antigny F, Noel S, Vandenbrouck C, Becq F. A CF respiratory cell chronically treated by miglustat acquires a non-CF like phenotype. Am J Respir Cell Mol Biol 2009 Jan 8 [Epub ahead of print].
23. van Doorninck JH, French PJ, Verbeek E, Peters RH, Morreau H, Bijman J, Scholte BJ. A mouse model for the cystic fibrosis delta F508 mutation. EMBO J 1995;14:4403-4411.
24. Nicklas W, Baneux P, Boot R, Decelle T, Deeny AA, Fumanelli M, Illgen-Wilcke B; FELASA (Federation of European Laboratory Animal Science Associations Working Group on Health Monitoring of Rodent and Rabbit Colonies). Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab Anim 2002;36:20-42. (Pubitemid 34073119)
25. Legssyer R, Huaux F, Lebacq J, Delos M, Marbaix E, Lebecque P, Lison D, Scholte BJ, Wallemacq P, Leal T. Azithromycin reduces spontaneous and induced inflammation in DEltaF508 cystic fibrosis mice. Respir Res 2006;7:134. (Pubitemid 44774213)
26. Minne A, Louahed J, Mahauden S, Baras R, Renauld JC, Vanbever R. The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response. Immunology 2007;122:316-325. (Pubitemid 47556468)
27. Platt FM, Neises GR, Karlsson GB, Dwek RA, Butters TD. N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. J Biol Chem 1994;269:27108-27114. (Pubitemid 2150955)
28. Leal T, Lebacq J, Vanbinst R, Lederman Ch, De Kock M, Wallemacq P. Successful protocol of anaesthesia for measuring transepithelial nasal potential difference in spontaneously breathing mice. Lab Anim 2006;40:43-52. (Pubitemid 43341082)
29. Knowles MR, Paradiso AM, Boucher RC. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1995;6:445-455.
30. Middleton PG, Geddes DM, Alton EW. Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium. Eur Respir J 1994;7:2050-2056. (Pubitemid 24366300)
31. Leal T, Fajac I, Wallace HL, Lebecque P, Lebacq J, Hubert D, Dall'Ava J, Dusser D, Ganesan AP, Knoop C, et al. Airway ion transport impacts on disease presentation and severity in cystic fibrosis. Clin Biochem 2008;41:764-772.
32. Colledge WH, Abella BS, Southern KW, Ratcliff R, Jiang C, Cheng SH, MacVinish LJ, Anderson JR, Cuthbert AW, Evans MJ. Generation and characterization of a delta F508 cystic fibrosis mouse model. Nat Genet 1995;10:445-452.
33. Zeiher BG, Eichwald E, Zabner J, Smith JJ, Puga AP, McCray PB Jr, Capecchi MR, Welsh MJ, Thomas KR. A mouse model for the delta F508 allele of cystic fibrosis. J Clin Invest 1995;96:2051-2064.
34. Dalby R, Suman J. Inhalation therapy: technological milestones in asthma treatment. Adv Drug Deliv Rev 2003;55:779-791. (Pubitemid 36776793)
35. Anderson MP, Sheppard DN, Berger HA, Welsh MJ. Chloride channels in the apical membrane of normal and cystic fibrosis airway and intestinal epithelia. Am J Physiol 1992;263:L1-L14.
36. Shcheynikov N, Wang Y, Park M, Ko SB, Dorwart M, Naruse S, Thomas PJ, Muallem S. Coupling modes and stoichiometry of Cl-/HCO3-exchange by slc26a3 and slc26a6. J Gen Physiol 2006;127:511-524.
37. Farinha CM, Amaral MD. Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin. Mol Cell Biol 2005;25:5242-5252. (Pubitemid 40781121)
38. Okiyoneda T, Niibori A, Harada K, Kohno T, Michalak M, Duszyk M, Wada I, Ikawa M, Shuto T, Suico MA, Kai H. Role of calnexin in the ER quality control and productive folding of CFTR: differential effect of calnexin knockout on wild-type and DeltaF508 CFTR. Biochim Biophys Acta 2008;1783:1585-1594.
39. Rosser MF, Grove DE, Chen L, Cyr DM. Assembly and misassembly of cystic fibrosis transmembrane conductance regulator: folding defects caused by deletion of F508 occur before and after the calnexin-dependent association of membrane spanning domain (MSD) 1 and MSD2. Mol Biol Cell 2008;19:4570-4579.
40. Mall M, Grubb BR, Harkema JR, O'Neal WK, Boucher RC. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med 2004;10:487-493. (Pubitemid 38667907)
41. Mall MA, Harkema JR, Trojanek JB, Treis D, Livraghi A, Schubert S, Zhou Z, Kreda SM, Tilley SL, Hudson EJ, et al. Development of chronic bronchitis and emphysema in beta-epithelial Na+ channel-overexpressing mice. Am J Respir Crit Care Med 2008;177:730-742.
42. Guilbault C, De Sanctis JB, Wojewodka G, Saeed Z, Lachance C, Skinner TA, Vilela RM, Kubow S, Lands LC, Hajduch M, et al. Fenretinide corrects newly found ceramide deficiency in cystic fibrosis. Am J Respir Cell Mol Biol 2008;38:47-56.